Steve Krognes, a director and former chief financial officer at Denali Therapeutics Inc, has joined the board of directors of argenx SE in the Netherlands as a non-executive director where he will also chair the company’s audit and compliance committee. Argenx is developing drugs for severe autoimmune diseases. Mr Krognes previously worked at Genentech and subsequently at Roche where he led global merger and acquisition activity. He holds a Master of Business Administration degree from Harvard Business School and a bachelor of science in economics from the Wharton School of the University of Pennsylvania, US.
argenx announced the appointment on 27 February 2023.
Copyright 2023 Evernow Publishing Ltd